Investigating the pathogenesis and development of therapeutics of alpha-synucleinopathy
Project/Area Number |
18H04041
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Review Section |
Medium-sized Section 52:General internal medicine and related fields
|
Research Institution | Kyoto University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
秋山 央子 国立研究開発法人理化学研究所, 脳神経科学研究センター, 研究員 (80623462)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥31,850,000 (Direct Cost: ¥24,500,000、Indirect Cost: ¥7,350,000)
Fiscal Year 2020: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2019: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2018: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
|
Keywords | パーキンソン病 / 多系統萎縮症 / αシヌクレイン / glucocerebrosidase |
Outline of Final Research Achievements |
Analysis of the two mice model for idiopathic Parkinson’s disease (PD), a-syn BAC Tg/GBA1 heterozygous KO mice and A53T mutant a-syn BAC Tg mice, revealed the region-specific increase in the amount of various kind of glycolipids, and cellular experiment suggested the conformational change of a-syn by altered lipid metabolism. To investigate the role of GBA2 gene as a modifier of GBA1 gene, we generated GBA2-/- (KO) medaka fish and GBA1/GBA2 double knockout medaka fish, and found that GBA2 deletion further increased the amount of specific glycolipids. Moreover, GBA1 was found to function as β-galactosidase, a GalCer degrading enzyme.
|
Academic Significance and Societal Importance of the Research Achievements |
モデル動物を使用した実験からパーキンソン病において脂質代謝異常がαシヌクレインの修飾を介して病態に関与しうること、孤発性パーキンソン病の最大の遺伝的リスク因子であるGBA1の修飾因子としてGBA2が存在することなどが判明し、治療のターゲット分子となりうることを示した。
|
Report
(2 results)
Research Products
(18 results)
-
-
-
[Journal Article] Glucocerebrosidases catalyze a transgalactosylation reaction that yields a newly-identified brain sterol metabolite, galactosylated cholesterol2020
Author(s)
Akiyama, H., Ide, M., Nagatsuka, Y., Sayano, T., Nakanishi, E., Uemura, N., Yuyama, K., Yamaguchi, Y., Kamiguchi, H., Takahashi, R., Aerts, J. M. F. G., Greimel, P. and Hirabayashi, Y
-
Journal Title
Journal of Biological Chemistry
Volume: 295
Issue: 16
Pages: 5257-5277
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
[Journal Article] a-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia:a prodromal Parkinson’s disease model2020
Author(s)
Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, Sawamura M, Okuda S, Nakanishi E, Hara J, Uemura N, Hatanaka Y, Ayaki T, Matsuzawa S, Tanaka M, El-Agnaf OMA, Koike M, Yanagisawa M, Uemura MT, Yamakado H, Takahashi R
-
Journal Title
BRAIN
Volume: 143
Issue: 1
Pages: 249-265
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
[Presentation] Newly identified brain sterol metabolite glycosylated sterols are metabolized by α-glucocerebrosidase 1 and 2 in vivo2019
Author(s)
Hisako Akiyama, Mitsuko Ide, Etsuro Nakanishi, Norihito Uemura, Yoshiki Yamaguchi, Hiroyuki Kamiguchi, Ryosuke Takahashi, Peter Greimel and Yoshio Hirabayashi
Organizer
25th International Symposium on Glycoconjugates, Milan, Italy,
Related Report
Int'l Joint Research
-
-
-
-